Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer

We aimed to increase pathologic complete response (pCR) in patients with invasive breast cancer by adding preoperative capecitabine to docetaxel following 5‐fluorouracil, epirubicin, cyclophosphamide (FEC) (with trastuzumab for patients with HER2‐positive disease) and to evaluate 5‐year disease‐free...

Descripción completa

Detalles Bibliográficos
Autores principales: Holmes, Frankie Ann, Hellerstedt, Beth A., Pippen, John E., Vukelja, Svetislava J., Collea, Rufus P., Kocs, Darren M., Blum, Joanne L., McIntyre, Kristi J., Barve, Minal A., Brooks, Barry D., Osborne, Cynthia R., Wang, Yunfei, Asmar, Lina, O'Shaughnessy, Joyce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010779/
https://www.ncbi.nlm.nih.gov/pubmed/29582557
http://dx.doi.org/10.1002/cam4.1472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010779/
https://www.ncbi.nlm.nih.gov/pubmed/29582557
http://dx.doi.org/10.1002/cam4.1472

Ejemplares similares